GLP-1 Poison-Center Calls Are Rising, With Dosing Errors a Repeated Theme

Poison-center calls involving GLP-1 receptor agonists are increasing, and dosing errors appear as a repeated theme in the available data. The trend matters because it tracks a real-world safety signal emerging alongside expanded use of the drug class, but the numbers require careful interpretation: poison-center calls are exposure reports, not confirmed poisonings or a population incidence rate.

What the exposure data show

Reports from poison centers indicate a rise in GLP-1-related calls as the medications have become more widely used for diabetes and weight management. Drug Topics and Drugs.com coverage both describe an increase in calls tied to the GLP-1 boom, with dosing errors identified as a notable pattern. A peer-reviewed analysis indexed at PubMed also examined the characteristics of these exposures, providing a clinical frame for what the call volumes represent.

The Washington Poison Center published insights on GLP-1s noting that exposure reports can involve a range of scenarios, including unintentional dosing errors. Common situations reflected in poison-center data include taking a dose too soon after a previous one, measuring a volume incorrectly, or confusing maintenance dosing with titration schedules.

Exposure calls are not confirmed poisonings

A central limitation is definitional. A poison-center exposure call means someone contacted the center about a potential or actual exposure. It does not mean the caller was poisoned, hospitalized, or even symptomatic. It also does not provide a population incidence rate, because call volume depends on who decides to contact a poison center and how centers aggregate reports.

This distinction matters for interpreting trend lines. A rise in calls could reflect more total users, more awareness of poison-center services, more access to injectable drugs that carry measurement complexity, or some combination of those factors. The data point to where risk is concentrated operationally, particularly around dosing, but they cannot by themselves establish that GLP-1 products are intrinsically more dangerous than before.

Dosing errors as a practical signal

The repeated appearance of dosing errors in the data is practically significant because it points to modifiable user behavior rather than unpredictable adverse events. GLP-1 agonists often require titration, scheduled dose escalation, and, for injectable formulations, careful volume measurement. Errors can occur when patients misunderstand the interval between doses, use the wrong concentration, or administer more than intended.

Because GLP-1s affect gastric emptying and glucose regulation, overexposure can produce gastrointestinal distress, nausea, and in more serious cases symptoms warranting medical evaluation. The clinical concern is not trivial, but it is also not uniform: many exposure calls involve managed outcomes at home with guidance from poison-center staff.

Approved products versus compounded products

It is important not to attribute every exposure event to compounded products. Poison-center reports generally capture the substance involved, but they do not always specify whether the product was an FDA-approved formulation or a compounded preparation. The rise in calls coincides with growth in both regulated pharmaceutical access and, where permitted, compounded GLP-1 production during shortage conditions.

Compounded products can introduce additional variables, such as differing concentrations, vial-and-syringe presentation, and pharmacy-specific labeling. Those factors can contribute to measurement confusion. However, approved products are also subject to dosing errors, particularly when patients are unfamiliar with injection devices or titration schedules. The safety signal spans both categories, and the available data do not justify assigning blame exclusively to either.

Why this development matters

The growth in GLP-1 exposure calls matters for three reasons. First, it identifies dosing as a leverage point for harm reduction: clearer labeling, patient education, and device design could reduce errors regardless of product source. Second, it highlights the need for surveillance systems that can distinguish between approved and compounded products when possible, so that risk attribution is evidence-based rather than assumed. Third, it underscores that expanding access to a complex drug class without proportional education can produce predictable error patterns.

Key limitations to keep in mind

• Poison-center calls are exposure reports, not confirmed poisonings.
• Call volumes do not represent a population incidence rate.
• Reports do not uniformly identify whether the product was approved or compounded.
• Symptom severity varies widely, and many exposures are managed without serious outcome.

The bottom line

The rise in GLP-1 poison-center calls is a genuine signal worth monitoring, and dosing errors are a consistent, actionable theme. But the data must be read with discipline. Exposure reports reflect contact with a safety system, not a count of poisonings, and they cannot be used to indict any single product category without further specification. The practical takeaway is that as GLP-1 use grows, the systems supporting safe administration, labeling, and patient understanding need to grow with it.